Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection
Charlotte Billiet(Hasselt University), Dirk De Ruysscher(Maastricht University Medical Centre), Jeroen Mebis(Jessa Hospital), Stéphanie Peeters(KU Leuven), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), Christophe M. Deroose(KU Leuven), C. Le Péchoux(Institut Gustave Roussy), Paul De Leyn(KU Leuven), Herbert Decaluwé(VIB-KU Leuven Center for Cancer Biology), Paul Bulens(Jessa Hospital), Johan Vansteenkiste, Md Rezaul Karim(Islamic University), Marc Hendrikx(Jessa Hospital)
Cited by 25
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Invasive Mediastinal Staging of Lung Cancer
|CHEST Journal|2007|688